An investigational cell therapy slowed the loss of arm and elbow function in boys and young men with advanced Duchenne muscular dystrophy (DMD), according to Phase 3 results published as U.S. regulators weigh whether to approve it.
The disease
Duchenne is a severe, progressive genetic muscle disease that affects roughly 1 in 3,500–5,000 boys. It is caused by mutations in the gene for dystrophin, a protein that acts like a shock absorber for muscle fibers; without it, muscle steadily breaks down. Boys typically lose the ability to walk in their teens, and the disease eventually affects the muscles of the heart and lungs. Preserving upper-limb function becomes especially important once walking is lost, because patients rely on their arms for daily independence — feeding, using a wheelchair, operating devices.
The therapy and the trial
The therapy, deramiocel, developed by Capricor Therapeutics, uses allogeneic (donor-derived) cardiosphere-derived cells — a cell population originally isolated from heart tissue that is thought to release factors that dampen inflammation and support muscle repair. In the HOPE-3 trial, 106 boys and young men aged 10 to 22 were randomized to deramiocel (54) or placebo (52) and given intravenous infusions every three months for one year across 20 U.S. sites.
What the trial showed
On measures of upper-limb function, decline was 54% slower for arm movement and 65% slower for elbow movement with deramiocel than with placebo. Slowing that decline in a relentlessly progressive disease is clinically meaningful, even if it does not reverse damage.
The heart data are less clear
DMD also damages the heart, and deramiocel was first studied for cardiac effects. Here the results were mixed: there was no clear overall difference in heart function between the groups. In a subgroup of 64 participants with existing heart disease, deramiocel was associated with better preservation of function, and 22 participants showed less spread of heart scarring — findings the researchers say require further confirmation.
Safety, and why it matters now
No deaths were reported. Allergic-type reactions were more common with deramiocel (42% vs 15%), but most side effects were mild to moderate and resolved within one to two days (headache, cough, fever, nausea, rapid heartbeat). The results were published on July 29, the same day an FDA advisory committee met to review the therapy, with an agency decision expected by August 22, 2026. For families facing a disease with few options, an approval would add a new tool — though the modest, region-specific benefits underline how incremental progress in DMD remains. Not medical advice.